Gracie, DJ orcid.org/0000-0001-9616-981X and Ford, AC orcid.org/0000-0001-6371-4359 (2016) The possible risks of proton pump inhibitors. The Medical Journal of Australia, 205 (7). pp. 292-293. ISSN 0025-729X
Abstract
Proton pump inhibitors (PPIs) suppress gastric acid secretion by selectively inhibiting the enzyme hydrogen–potassium adenosine triphosphatase, located in gastric parietal cells. These drugs superseded H2-receptor antagonists as first-line acid suppressants in the 1980s, and their potent effect has revolutionised the management of common upper gastrointestinal (GI) disorders, including gastro-oesophageal reflux disease, peptic ulcer disease, and functional dyspepsia. These drugs are also widely used as part of regimens designed to eradicate Helicobacter pylori infection, and as prophylaxis against the deleterious effects of non-steroidal anti-inflammatory drugs on the GI tract.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Molecular Gastroenterology (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 11 Oct 2017 10:17 |
Last Modified: | 12 Oct 2017 08:25 |
Status: | Published |
Publisher: | Australasian Medical Publishing Company Ltd |
Identification Number: | 10.5694/mja16.00750 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:122321 |